Status:
COMPLETED
Human Chorionic Gonadotrophin in an Antagonist Protocol
Lead Sponsor:
Cairo University
Conditions:
Infertility
Eligibility:
FEMALE
20-40 years
Phase:
PHASE2
PHASE3
Brief Summary
A novel gonadotropin protocol for ovarian stimulation adds low-dose hCG (50- 200 IU) as a source of LH (luteinizing hormone) in the late follicular phase . This regimen reduces the number of small pr...
Detailed Description
* 60 women, where 30 of them will receive low dose HCG with rFSH (group 1), while the other 30 women will receive rFSH (Recombinant Follicle stimulating Hormone) with a placebo (group 2) both using th...
Eligibility Criteria
Inclusion
- Indication for ICSI treatment.
- The presence of one or two functional ovaries.
- Good responders to ovarian stimulation.
- The presence of normal uterine cavity
- Basal (day 2 or 3) serum FSH (follicle stimulating Hormone) levels ≤13 IU
- No untreated endocrinologic disease
Exclusion
- Abnormal uterine cavity.
- Basal (day 2 or 3) serum FSH levels ≥13 IU.
- Poor responders to ovarian stimulation according to the existence of at least two of the following criteria:Advanced maternal age (above 40 years), antral follicles count \<5, prior history of poor response to controlled ovarian hyperstimulation (peak E2 \<500 pg/ml and/or ≤3 oocytes retrieved).
- Untreated endocrinologic disease.
- Azoospermia. all patients should be managed in Cairo,Egypt
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01833858
Start Date
August 1 2013
End Date
January 1 2015
Last Update
February 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Cairo Governorate, Egypt